v2.4.0.6
Collaborations (Details)
 1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 3 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 3 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 3 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended
Mar. 31, 2010
USD ($)
Dec. 31, 2011
USD ($)
Dec. 31, 2010
USD ($)
Dec. 31, 2009
USD ($)
Dec. 31, 2011
Erbitux [Member]
USD ($)
Dec. 31, 2010
Erbitux [Member]
USD ($)
Dec. 31, 2009
Erbitux [Member]
USD ($)
Dec. 31, 2011
Effient [Member]
USD ($)
Dec. 31, 2010
Effient [Member]
USD ($)
Dec. 31, 2009
Effient [Member]
USD ($)
Nov. 30, 2011
Amylin [Member]
USD ($)
Dec. 31, 2011
Exenatide [Member]
USD ($)
Dec. 31, 2010
Exenatide [Member]
USD ($)
Dec. 31, 2009
Exenatide [Member]
USD ($)
Jan. 31, 2011
Boerhringer Ingelheim (BI) [Member]
USD ($)
Nov. 30, 2011
Sales NEW [Member]
Amylin [Member]
Dec. 31, 2011
Sales NEW [Member]
Exenatide [Member]
Nov. 30, 2011
Revenue Share [Member]
Amylin [Member]
USD ($)
Dec. 31, 2011
Gross Margin Share [Member]
Exenatide [Member]
Sep. 30, 2010
Profit and Development and Marketing Share [Member]
Effient [Member]
Dec. 31, 2011
Selling and Marketing Expense [Member]
Necitumumab [Member]
Mar. 31, 2010
Prepaid Selling and Marketing Expense [Member]
Duloxetine BI [Member]
USD ($)
Dec. 31, 2011
Royalty Payments Received [Member]
Solanezumab [Member]
USD ($)
Dec. 31, 2011
Research and Development Exp [Member]
Necitumumab [Member]
Dec. 31, 2011
Research and Development and Marketing and Selling Expense [Member]
Exenatide [Member]
Dec. 31, 2011
Milestone Payments [Member]
Necitumumab [Member]
USD ($)
Nov. 30, 2011
Milestone Payments [Member]
Amylin [Member]
USD ($)
Sep. 30, 2011
Milestone Payments [Member]
Solanezumab [Member]
USD ($)
Jan. 31, 2011
Milestone Payments [Member]
BI compounds [Member]
EUR (€)
Dec. 31, 2011
Milestone Payments [Member]
BI compounds [Member]
USD ($)
Jan. 31, 2011
Milestone Payments [Member]
LLY compounds [Member]
USD ($)
Jan. 31, 2011
Milestone Payments [Member]
LLY optional compound [Member]
USD ($)
Jun. 30, 2011
Loan Commitment [Member]
Exenatide Once Weekly [Member]
USD ($)
Nov. 30, 2011
United States [Member]
Revenue Share [Member]
Amylin [Member]
Dec. 31, 2011
United States [Member]
Research and Development Exp [Member]
Necitumumab [Member]
Nov. 30, 2011
Outside the United States [Member]
Revenue Share [Member]
Amylin [Member]
Dec. 31, 2011
Outside the United States [Member]
Research and Development Exp [Member]
Necitumumab [Member]
Net product sales   $ 23,604,800,000 $ 22,442,200,000 $ 21,171,500,000 $ 87,600,000 $ 71,900,000 $ 92,500,000 $ 302,500,000 $ 115,000,000 $ 27,000,000   $ 179,600,000 $ 168,100,000 $ 147,700,000                                              
Collaboration and other revenue   681,700,000 633,800,000 664,500,000 321,600,000 314,200,000 298,300,000         243,100,000 262,500,000 300,800,000                                              
Revenue   24,286,500,000 23,076,000,000 21,836,000,000 409,200,000 386,100,000 390,800,000         422,700,000 430,600,000 448,500,000                                              
Research and development   5,020,800,000 4,884,200,000 4,326,500,000                                                                  
Collaborative Arrangement, Income Statement Classification and Amounts   219,200,000 174,500,000 319,200,000                                                                  
Collaborative Arrangement, Rights and Obligations                     250,000,000             1,200,000,000       400,000,000 8     250,000,000 150,000,000 70,000,000 300,000,000 478,700,000 650,000,000 525,000,000 165,000,000        
Collaborative Arrangement, Rights and Obligations Percent                               15.00% 100.00% 9.50% 50.00% 50.00% 50.00%     45.00% 50.00%                 65.00% 45.00% 35.00% 72.50%
Acquired in-process research and development $ 50,000,000 $ 388,000,000 $ 50,000,000 $ 90,000,000                     $ 388,000,000